Holen Sie sich die Stockscreener-App
18.15
7.65%
1.29
Schlusskurs vom Vortag:
$16.86
Offen:
$16.84
24-Stunden-Volumen:
281.23K
Relative Volume:
1.46
Marktkapitalisierung:
$617.39M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-81.05M
KGV:
-6.919
EPS:
-2.6232
Netto-Cashflow:
$-68.97M
1W Leistung:
+10.54%
1M Leistung:
-19.26%
6M Leistung:
-35.73%
1J Leistung:
+2.72%
1-Tages-Spanne:
$16.31
$18.17
1-Wochen-Bereich:
$15.47
$18.17
52-Wochen-Spanne:
$14.35
$36.37
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Firmenname
Arrivent Biopharma Inc
Sektor
Branche
Telefon
240-780-6356
Adresse
18 CAMPUS BLVD., NEWTOWN SQUARE
Vergleichen Sie AVBP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
18.15 | 617.39M | 0 | -81.05M | -68.97M | -2.6232 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.22 | 122.24B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.18 | 59.73B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.94 | 35.43B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
237.77 | 30.77B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
96.52 | 23.20B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-20 | Eingeleitet | B. Riley Securities | Buy |
| 2025-03-10 | Eingeleitet | Guggenheim | Buy |
| 2024-07-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-20 | Eingeleitet | Citigroup | Buy |
| 2024-02-20 | Eingeleitet | Goldman | Buy |
| 2024-02-20 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Arrivent Biopharma Inc Aktie (AVBP) Neueste Nachrichten
KLP Kapitalforvaltning AS Purchases New Shares in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Corebridge Financial Inc. Has $373,000 Stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
(AVBP) Trading Report - news.stocktradersdaily.com
Swiss National Bank Buys Shares of 26,400 ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Arbutus Biopharma Reports 2024 Financial Results and Strategic Updates - MyChesCo
Aprea Therapeutics Reports 2024 Financial Results and Updates on Clinical Innovations - MyChesCo
Charles Schwab Investment Management Inc. Has $5.50 Million Stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Brokers Offer Predictions for AVBP Q1 Earnings - Defense World
Brokerages Set ArriVent BioPharma, Inc. (NASDAQ:AVBP) Target Price at $39.40 - Defense World
B. Riley Begins Coverage on ArriVent BioPharma (NASDAQ:AVBP) - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Upgraded at B. Riley - Defense World
B.Riley sets $37 target on ArriVent stock, initiates with Buy - Investing.com Canada
ArriVent Lead Drug Candidate Shows Promise In Lung Cancer Type, Analyst Sees Over 50% Upside - Benzinga
This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
B. Riley Initiates ArriVent BioPharma at Buy With $37 Price Target -March 20, 2025 at 07:13 am EDT - MarketScreener
ArriVent Biopharma initiated with a Buy at B. Riley - TipRanks
ArriVent BioPharma (AVBP) Projected to Post Quarterly Earnings on Thursday - Defense World
ArriVent BioPharma (AVBP): Among the Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey
10 Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey
ArriVent BioPharma reports FY results - MSN
(AVBP) Technical Pivots with Risk Controls - news.stocktradersdaily.com
ArriVent BioPharma appoints PwC as new auditor - Investing.com India
ArriVent BioPharma appoints PwC as new auditor By Investing.com - Investing.com South Africa
ArriVent BioPharma (NASDAQ:AVBP) Now Covered by Analysts at Guggenheim - Defense World
Oppenheimer starts ArriVent BioPharma at outperform - MSN
Guggenheim starts ArriVent Biopharma with a Buy on firmonertinib potential - TipRanks
Financial Contrast: ArriVent BioPharma (AVBP) and The Competition - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Earns “Buy” Rating from HC Wainwright - Defense World
Here's What Could Help ArriVent BioPharma, Inc. (AVBP) Maintain Its Recent Price Strength - MSN
H.C. Wainwright maintains Buy on ArriVent shares, $39 target By Investing.com - Investing.com Canada
ArriVent BioPharma Reports 2024 Financial Results and Key Achievements - MSN
H.C. Wainwright maintains Buy on ArriVent shares, $39 target - Investing.com India
Rhumbline Advisers Purchases 3,069 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
FY2025 EPS Estimates for AVBP Reduced by Lifesci Capital - Defense World
New York State Common Retirement Fund Boosts Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma Reports 2024 Financial Results and Progress - MSN
(AVBP) Investment Report - Stock Traders Daily
Lepu Biopharma Co., Ltd. Announces Update on New Drug Application of MRG003 -March 03, 2025 - Marketscreener.com
ArriVent BioPharma, Inc. SEC 10-K Report - TradingView
ArriVent BioPharma Reports Full Year 2024 Financial Results - The Manila Times
Arbutus Biopharma Appoints Lindsay Androski as CEO Amid Leadership Restructuring - MyChesCo
IPOs Numbers Rise In 2024, But Dwindling Returns Could Diminish Potential In 2025 - insights.citeline.com
Where are the Opportunities in (AVBP) - Stock Traders Daily
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Update - MarketBeat
Mirae Asset Global Investments Co. Ltd. Makes New Investment in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Mirae Asset Global Investments Co. Ltd. Purchases Shares of 1,123 ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Armenian Reporter
How To Trade (AVBP) - Stock Traders Daily
Short Interest in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Expands By 13.1% - MarketBeat
Deal Watch: Novo Nordisk, IMMvention To Partner On Sickle Cell Disease - News & Insights
Asia’s NewCo Model, FDA tipping point, Vertex’s pain drug: a BioCentury podcast - BioCentury
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Bought by JPMorgan Chase & Co. - Defense World
Finanzdaten der Arrivent Biopharma Inc-Aktie (AVBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):